共 50 条
Sensitive PCR-based quantitation of cell-free circulating microRNAs
被引:34
|作者:
Hastings, Michelle L.
[1
]
Palma, Jaime
[2
]
Duelli, Dominik M.
[1
,2
]
机构:
[1] Rosalind Franklin Univ Med & Sci, Dept Cell Biol & Anat, N Chicago, IL 60064 USA
[2] Rosalind Franklin Univ Med & Sci, Dept Cellular & Mol Pharmacol, N Chicago, IL 60064 USA
来源:
基金:
美国国家卫生研究院;
关键词:
MicroRNA;
Plasma;
Circulating;
PCR;
MESSENGER-RNA;
HEPARINASE TREATMENT;
DNA AMPLIFICATION;
SERUM;
CANCER;
PLASMA;
QUANTIFICATION;
BIOMARKERS;
BLOOD;
INHIBITORS;
D O I:
10.1016/j.ymeth.2012.07.026
中图分类号:
Q5 [生物化学];
学科分类号:
071010 ;
081704 ;
摘要:
Cell-free microRNAs (miRNAs) that circulate in the blood are promising surrogate biomarkers of disease and physiological processes. The ease of quantifying specific miRNA species using made-to-order approaches based on Taq-polymerase has led to numerous studies that have identified changes in the abundance of circulating cell-free miRNA species that correlate with pathology or other events. The growing interest in developing miRNAs as blood biomarkers necessitates the careful consideration of the unique properties of such body fluids that can make the reproducible and quantitative assessment of RNA abundance challenging. For example, enzymes involved in the amplification and analysis of RNA can be affected by blood components that copurify with miRNA. Thus, if miRNAs are to be effectively utilized as biomarkers, it is important to establish standardized protocols for blood collection and miRNA analysis to ensure accurate quantitation. Here we outline several considerations, including the type of collection tube used in sampling, the influence of added anticoagulants and stabilizers, sample processing, enrichment of vesicular and other miRNA species, RNA extraction approaches and enzyme selection, that affect quantitation of miRNA isolated from plasma and should be considered in order to achieve reproducible, sensitive and accurate quantitation. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:144 / 150
页数:7
相关论文